Hormonal
GLP-1 agonists (semaglutide, tirzepatide) produce significant weight loss (15-21%) but are associated with isolated reports of depression and suicidal ideation, though causal links remain unproven.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss (15-21%), but require careful psychological monitoring. While serious mental health side effects are reported, they are isolated and not causally proven. You should undergo regular mental health check-ins alongside your medical treatment to ensure safety.
Os estudos mostraram eficácia de semaglutida e tirzepatida na perda ponderal (15%–21%)... Foram relatados casos isolados de depressão e ideação suicida com agonistas de GLP-1, sem causalidade comprovada.
Why this rating
Based on an integrative review of 12 studies including RCTs and cohorts, but notes lack of causal proof for psychiatric effects.
Source
SAÚDE MENTAL NO EMAGRECIMENTO: EFEITOS ADVERSOS DE NOVAS TERAPIAS FARMACOLÓGICAS
Kelli Maria Alvarenga de Macedo et al. · Revista Foco · 2025
DOI 10.54751/revistafoco.v18n11-117
More from this paper
- Multidisciplinary follow-up integrating pharmacotherapy, psychology, and nutrition significantly improves therapeutic adherence, mental health outcomes, and weight loss maintenance compared to pharmacotherapy alone.Good
- Naltrexone/Bupropion combination therapy offers good psychiatric tolerability with only mild, transient anxiety and insomnia, making it a safe alternative for patients concerned about mood stability.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →